GlassScriptPhysician profile
Markand J Patel
NPI 1619266806
$3,052.38
in general payments reported to CMS, 2019-2025
28 companies · $425 in 2025
The $425 reported for 2025 was more than what 76% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $183 · 2021: $390 · 2022: $387 · 2023: $426 · 2024: $198 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $658.58 | 2019-2025 | Watchman Flx, Infinion 16, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $462.91 | 2022-2024 | Intellis Adaptivestim, Synchromedii, Osteocool Rf Ablation System |
| Abbott Laboratories | $406.55 | 2019-2022 | |
| Vertiflex, INC. | $242.96 | 2019 | |
| Collegium Pharmaceutical, INC. | $181.83 | 2019-2025 | Belbuca, Xtampza |
| Amarin Pharma, INC. | $124.97 | 2019 | |
| Pfizer INC. | $120.63 | 2019-2020 | |
| Foundation Fusion Solutions, LLC | $91.47 | 2023 | |
| Nevro Corp. | $88.71 | 2019-2022 | |
| Mml US, INC. | $85.50 | 2025 | Reactiv8 |
| Daiichi Sankyo INC. | $84.07 | 2019 | |
| Averitas Pharma INC. | $78.62 | 2023-2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.34 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $40.56 | 2025 | |
| Horizon Therapeutics Plc | $40.09 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $36.47 | 2025 | Roxybond |
| Medtronic USA, INC. | $36.38 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $30.71 | 2022 | |
| Biotronik Nro, INC. | $28.12 | 2025 | Prospera |
| Abbvie INC. | $24.47 | 2022 | |
| Relievant Medsystems, INC. | $23.21 | 2023 | Intracept |
| Merck Sharp & Dohme LLC | $19.90 | 2019 | |
| Fidia Pharma USA INC. | $19.88 | 2022 | |
| Biodelivery Sciences International, INC. | $15.27 | 2020 | |
| Globus Medical, INC. | $14.64 | 2025 | Vyrsa V1 |
| Scilex Pharmaceuticals INC. | $14.38 | 2019 | |
| Lilly USA, LLC | $12.11 | 2020 | |
| Electronic Waveform Lab, INC. | $9.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Markand Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.